- Home
- RARE
as 12-20-2024 3:41pm EST
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 5.2B | IPO Year: | 2014 |
| Target Price: | $88.43 | AVG Volume (30 days): | 717.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $37.02 - $60.37 | Next Earning Date: | 02-13-2025 |
| Revenue: | $522,745,000 | Revenue Growth: | 27.44% |
| Revenue Growth (this year): | 27.36% | Revenue Growth (next year): | 18.61% |
Stock Insider Trading Activity of Ultragenyx Pharmaceutical Inc. (RARE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Horn Howard | RARE | Chief Financial Officer | Oct 10 '24 | Sell | $52.76 | 7,465 | $393,853.40 | 92,301 |
Latest Ultragenyx Pharmaceutical Inc. News
RARE Breaking Stock News: Dive into RARE Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zacks
2 days ago
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
GlobeNewswire
2 days ago
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)
MT Newswires
3 days ago
Ultragenyx Reports Patient Dosing in Angelman Syndrome Trial
GlobeNewswire
3 days ago
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
MT Newswires
3 days ago
Ultragenyx Seeks FDA Accelerated Approval for Gene Therapy to Treat Sanfilippo Syndrome
GlobeNewswire
3 days ago
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
GlobeNewswire
a month ago
Ultragenyx to Participate in Investor Conferences in December
Compare RARE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RARE Ultragenyx Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.